With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.
With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.
Mind Cure has acquired Epiphany360, a digital therapeutics platform for the treatment of mental health conditions.
Pharmather is seeking to advance a ketamine-based therapy for the treatment of Parkinson's disease.
Revive has signed a psychedelics supply agreement with HAVN Life Sciences.
Psychedelic drug stocks may represent the best investing strategy to hedge against COVID-19 economic risks.
Cybin Corp. announces it has closed on an oversubscribed private placement of CAD$45 million as it prepares to go public.
The Compass Pathways IPO was a huge catalyst for the whole sector. Will a MindMed up-listing have the same impact?
Mydecine begins the dual listing process to obtain an LSE listing.
What is medtech? It's the wave of the future for healthcare.
Mind Cure brings in an expert in fintech to be its new CTO.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now